Home›Talimogene Laherparepvec›Talimogene Laherparepvec + Acyclovir

Does Talimogene Laherparepvec Interact with Acyclovir?

Talimogene Laherparepvec and Acyclovir have a major drug interaction according to U.S. FDA drug labeling data. Acyclovir may interfere with the effectiveness of IMLYGIC (talimogene laherparepvec). IMLYGIC is sensitive to acyclovir. The mechanism involves antiherpetic viral agent interference with viral oncolytic activity. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Acyclovir Class
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Talimogene Laherparepvec and Acyclovir occurs because antiherpetic viral agent interference with viral oncolytic activity. Clinically, this means acyclovir may interfere with the effectiveness of imlygic (talimogene laherparepvec). imlygic is sensitive to acyclovir. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Talimogene Laherparepvec and your doctor is considering prescribing Acyclovir (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Talimogene Laherparepvec(Imlygic)+💊 Acyclovir(Sitavig)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
Source
NLP:talimogene laherparepvec

What this means in plain English

Acyclovir may interfere with the effectiveness of IMLYGIC (talimogene laherparepvec). IMLYGIC is sensitive to acyclovir.

About Talimogene Laherparepvec and Acyclovir

Acyclovir is a Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor. You may recognize them by the brand names Imlygic and Sitavig. Talimogene Laherparepvec is given by the intralesional route, whereas Acyclovir is applied to the skin.

What the FDA label says

"Antiherpetic viral agent interference with viral oncolytic activity"

📖 Source: NLP:talimogene laherparepvec

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Talimogene Laherparepvec and Acyclovir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.